• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cosette Pharmaceuticals Appoints Erika Tooman as Senior Vice President, General Counsel, Strengthening Leadership Team to Drive Accelerated Growth and Strategic Expansion

    4/29/26 8:15:00 AM ET
    $HLNE
    Investment Managers
    Finance
    Get the next $HLNE alert in real time by email

    -- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum --

    Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/

    Erika brings more than two decades of experience guiding pharmaceutical companies through periods of transformation, transaction activity, and operational scale. In her role at Cosette, she will oversee all legal, compliance, governance, and risk management matters, serving as a strategic advisor to the executive team and Board of Directors. Erika will play a central role in supporting Cosette's active business development agenda and ensuring robust governance as the company continues to expand through strategic acquisitions and partnerships.

    "Erika has built her career at the intersection of law, strategy, and enterprise value," said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. "As Cosette enters its next phase of growth – expanding our portfolio, integrating new assets and scaling our platform, Erika's ability to navigate complexity will be critical. Erika will be a key partner as we continue executing towards our long-term vision."

    Most recently, Erika served as Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer at Radius Health, where she was a core member of the executive team and played a central role in major litigation outcomes, royalty monetization transactions, and strategic M&A initiatives. Earlier in her career, she held senior leadership positions at Currax Pharmaceuticals and Pernix Therapeutics, and served as Senior Patent Counsel at Ikaria, contributing to significant exclusivity extensions and value realization ahead of its acquisition.

    "Cosette has built a strong platform with an ambitious vision for growth," said Erika Tooman, Senior Vice President, General Counsel, Cosette Pharmaceuticals. "I'm excited to join a leadership team that values rigor, partnership, and long‑term thinking. I look forward to helping Cosette navigate complexity, and support strategic initiatives that drive durable value for patients, partners, and shareholders."

    Erika earned her Juris Doctor from Brooklyn Law School, a Master of Biotechnology from Columbia University, and a Bachelor of Arts in Biology from Franklin & Marshall College. She is admitted to practice in New York and New Jersey and is registered with the U.S. Patent and Trademark Office. She has been recognized by Thomson Reuters as a Trailblazing Woman and by the Healthcare Businesswomen's Association for leadership excellence.

    About Cosette Pharmaceuticals

    Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine — developing, and delivering products that make a difference in patients' lives. Cosette's strong growth has been driven by its best-in-class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies. Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (NASDAQ:HLNE). For more information, please visit www.cosettepharma.com or follow Cosette on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260429022652/en/

    Cosette Pharmaceuticals:

    Media:

    media@cosettepharma.com

    Get the next $HLNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLNE

    DatePrice TargetRatingAnalyst
    4/16/2026$166.00Neutral → Overweight
    Analyst
    12/11/2025$166.00Buy
    UBS
    11/6/2025$165.00Neutral → Buy
    Goldman
    10/14/2025$181.00Perform → Outperform
    Oppenheimer
    10/13/2025$150.00Mkt Perform → Outperform
    Keefe Bruyette
    10/3/2025$150.00Outperform
    BMO Capital Markets
    9/18/2025$162.00Sell → Neutral
    Goldman
    5/15/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $HLNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HAMILTON LANE INCORPORATED REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS

    CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t

    5/21/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)

    — Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible

    5/19/26 8:12:00 AM ET
    $HLNE
    Investment Managers
    Finance

    MidOcean Announces Successful Close of Single-Asset Continuation Vehicle for Cloyes

    MidOcean Partners ("MidOcean"), a premier New York-based alternative asset manager specializing in middle-market private equity, alternative credit, and structured equity, today announced the closing of a single-asset continuation vehicle for Cloyes Gear and Products, Inc. ("Cloyes" or the "Company"), the North American leader and global designer, developer, manufacturer, and distributor of mission-critical timing drive systems and components for the automotive aftermarket. The continuation vehicle secured approximately $300 million in commitments, with funds managed by Hamilton Lane (NASDAQ:HLNE) serving as sole lead investor. In connection with the continuation vehicle, MidOcean-managed

    5/4/26 9:30:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Co-Chairman Rogers Hartley R. bought $9,992,338 worth of shares (110,932 units at $90.08) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    5/28/26 4:54:55 PM ET
    $HLNE
    Investment Managers
    Finance

    Director Berkman David J bought $1,010,000 worth of shares (10,000 units at $101.00) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/25/26 4:06:57 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Hirsch Erik R. bought $988,260 worth of shares (9,225 units at $107.13), increasing direct ownership by 15% to 70,494 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/24/26 4:07:41 PM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Kramer Andrea Anigati was granted 3,605 shares, increasing direct ownership by 4% to 86,067 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 5:01:50 PM ET
    $HLNE
    Investment Managers
    Finance

    Chief Accounting Officer Carl Drew Thomas was granted 675 shares, increasing direct ownership by 58% to 1,846 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 4:56:22 PM ET
    $HLNE
    Investment Managers
    Finance

    Chief Financial Officer Armbrister Jeffrey Brian was granted 2,109 shares, increasing direct ownership by 19% to 12,958 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    6/2/26 4:48:51 PM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Hamilton Lane Incorporated

    SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)

    5/29/26 6:07:21 PM ET
    $HLNE
    Investment Managers
    Finance

    SEC Form 10-K filed by Hamilton Lane Incorporated

    10-K - Hamilton Lane INC (0001433642) (Filer)

    5/21/26 4:30:52 PM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Hamilton Lane INC (0001433642) (Filer)

    5/21/26 7:00:02 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hamilton Lane upgraded by Analyst with a new price target

    Analyst upgraded Hamilton Lane from Neutral to Overweight and set a new price target of $166.00

    4/16/26 7:58:32 AM ET
    $HLNE
    Investment Managers
    Finance

    UBS resumed coverage on Hamilton Lane with a new price target

    UBS resumed coverage of Hamilton Lane with a rating of Buy and set a new price target of $166.00

    12/11/25 9:09:19 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane upgraded by Goldman with a new price target

    Goldman upgraded Hamilton Lane from Neutral to Buy and set a new price target of $165.00

    11/6/25 8:41:24 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Financials

    Live finance-specific insights

    View All

    HAMILTON LANE INCORPORATED REPORTS FOURTH QUARTER AND FISCAL YEAR 2026 RESULTS

    CONSHOHOCKEN, Pa., May 21, 2026 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth quarter and full fiscal year ended March 31, 2026. The Company issued a full detailed presentation of its fourth quarter and full fiscal year 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/.DividendHamilton Lane has declared a quarterly dividend of $0.60 per share of Class A common stock to record holders at the close of business on June 18, 2026 that will be paid on July 7, 2026. The target full-year dividend of $2.40 represents a 11% increase from t

    5/21/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Incorporated to Announce Fourth Fiscal Quarter and Full Fiscal Year 2026 Results on May 21, 2026

    CONSHOHOCKEN, Pa., April 23, 2026 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2026 before the market opens on Thursday, May 21, 2026. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 21 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here at least 15 minutes prior to the start of the call. This f

    4/23/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Announces Strategic Investment in Republic

    CONSHOHOCKEN, Pa. and NEW YORK, March 17, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, today announced a strategic investment in Republic, a leading on-chain global investment platform, reinforcing the firms' shared commitment to expanding retail investor access to institutional-quality private market funds. The investment builds on the existing partnership between Hamilton Lane and Republic, and underscores Hamilton Lane's long-term strategy to modernize and expand access to private markets. Together, the firms are enabling broader participation in the private markets asset class, which has historically been limited to institutions and

    3/17/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Leadership Updates

    Live Leadership Updates

    View All

    Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)

    — Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth — Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions – including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible

    5/19/26 8:12:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Cosette Pharmaceuticals Appoints Erika Tooman as Senior Vice President, General Counsel, Strengthening Leadership Team to Drive Accelerated Growth and Strategic Expansion

    -- Experienced life sciences executive to lead legal, compliance, and governance as Cosette scales its platform following recent acquisitions and continued growth momentum -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today that it has appointed Erika Tooman as Senior Vice President and General Counsel, strengthening the company's executive leadership team as it advances its long‑term growth, portfolio expansion, and value‑creation strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429022652/en/ Erika brings more than two decades of experience guiding pharmaceutica

    4/29/26 8:15:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Leading asset managers to join new Corastone platform as investors alongside Apollo, Franklin Templeton and KKR

    Expanded institutional participation underscores growing demand for private market opportunities and standardized operating infrastructureNEW YORK, March 9, 2026 /PRNewswire/ -- Corastone, the hyperscaler for private-market investing, today announced Fidelity Investments, Future Standard, and Hamilton Lane (NASDAQ:HLNE) as investors in Corastone and its alternative-investing operating platform. This growing institutional participation builds on Corastone's recent platform launch and comes as demand for private markets investments expands across investor types. As global private

    3/9/26 9:05:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $HLNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/4/24 11:53:29 AM ET
    $HLNE
    Investment Managers
    Finance